Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Contact information


parminder.judge@ndph.ox.ac.uk

Parminder Judge

MBChB, MRCP (Nephrol), PhD

Associate Professor

  • Associate Professor
  • Honorary Consultant Nephrologist, Oxford Kidney Unit
Parminder K Judge is an Associate Professor based in the Renal Studies Group at the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) and a practising Honorary Consultant Nephrologist at the Oxford Kidney Unit. Her research predominantly focuses on clinical trials testing new treatments aimed at managing and reducing the progression of chronic kidney disease and associated risk of cardiovascular disease.

She is Co-Principal Investigator of the EASi-KIDNEYTM trial which is testing the effects of vicadrostat (BI 690517; a novel aldosterone synthase inhibitor) versus placebo, in combination with empagliflozin 10mg, on cardiorenal outcomes in about 11,000 people with chronic kidney disease with and without diabetes.

Her epidemiological research aims to better understand kidney disease development and progression using observations from large blood-based prospective cohorts in South Asians. She has a particular interest in studying cardio-kidney-metabolic disorders among South Asians and the interplay with adiposity. She also has an active interest in teaching clinical trainees, undergraduate and postgraduate students.

Parminder studied medicine at the University of Birmingham. After completing her medical training, she undertook specialty training in nephrology in the Oxford rotation. In 2013, she took time ‘out-of-programme for research’ to work on clinical trials and led the UK HARP-III trial comparing the effects of sacubitril/valsartan (an angiotensin-receptor neprilysin inhibitor) with irbesartan (an angiotensin receptor blocker) in 400 people with chronic kidney disease. She also worked on the landmark 3C transplantation trial during this time. After completing her nephrology specialty training, Parminder returned to CTSU in 2020 to work on clinical trials in nephrology and cardiovascular disease, including the EMPA-KIDNEY and ORION-4 trials.